The role of anti-Saccharomyces cerevisiae antibody in early diagnosis of Crohn’s disease

Česká verze

Authors: V. Hrabovský ¹; A. Mendlová ¹; T. Posolda ²; H. Fikoczek ³; J. Dvořáčková ⁴; J. Ehrmann ⁴; M. Rydlo ⁵
Authors place of work: Metabolická JIP, Interní klinika, FN Ostrava2Chirurgická klinika, FN Ostrava3Radiodiagnostický ústav, FN Ostrava4Ústav patologie, FN Ostrava5Centrum digestivní endoskopie, FN Ostrava ¹
Published in the journal: Gastroent Hepatol 2010; 64(3): 7-12
Category: Kazuistika

Summary

Crohn’s disease (CD) is a chronic inflammatory process that may affect any part of the gastrointestinal tract. The active phase of the disease is usually connected with malnutrition and dyspepsia. The etiology of CD is still unknown and therefore treatment of the cause is impossible. Routine diagnosis is based on the results of blood analysis, X-ray, endoscopic and histological examinations. Immunological assay is also beneficial because ASCA (Anti-Saccharomyces Cerevisiae Antibody) is considered a typical immunological test for CD. Simultaneously, disease activity can be monitored by some tests, most frequently by plasma levels of CRP (C-reactive protein).

The aim of this article is to demonstrate the nine-year asymptomatic mild elevation of CRP and ASCA positivity in a young woman, in which severe active CD has subsequently developed.

Key words:
Crohn’s disease – inflammatory bowel disease – anti-Saccharomyces cerevisiae antibody

Zdroje

1. Regueiro MD. Update in Medical Treatment of Crohn´s Disease. J Clin Gastroenterol 2000; 31: 282–291.

2. Myrelid P, Olaison G, Sjödahl R et al. Thiopurine therapy is associated with postoperative intra-abdominal septic complications in abdominal surgery for Crohn´s disease. Dis Colon Rectum 2009; 52(8): 1387–1394.

3. Sandborn WJ, Hanauer SB, Rutgeerts P et al. Adalimumab for maintenance treatment of Crohn‘s disease: results of the CLASSIC II trial. Gut 2007; 56(9): 1232–1239.

4. Lochs H. Nutritional support in inflammatory bowel disease. In: Sobotka L.: Basics in clinical nutrition, Edited for ESPEN courses, second edition. Galen 2000: 300.

5. Pizarro TT, De La Rue SA, Cominelli F. Role of interleukin 6 in a murine model of Crohn‘s ileitis: are cytokine/anticytokine strategies the future for IBD therapies? Gut 2006; 55(9): 1226–1227.

6. Winter TA, Lemmer ER, O´Keefe SJ et al. The effect of severe undernutrition, and subsequent refeeding on digestive function in human patients. Eur J Gastroenterol Hepatol 2000; 12(2): 191–196.

7. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestation and complications in inflammatory bowel diseases. World J Gastroenterol 2006; 12(30): 4819–4831.

8. Lukáš M. Idiopatické střevní záněty a kolorektální karcinom. Nové souvislosti a další perspektivy. Čes a Slov Gastroenterol Hepatol 2006; 60: 113–118.

9. Solem CA, Loftus EV Jr, Fletcher JG et al. Small-bowel imaging in Crohn‘s disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc 2008; 68(2): 255–266.

10. Colombel JF, Solem CA, Sandborn WJ et al. Quantitative measurement and visual assessment of ileal Crohn´s disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein. Gut 2006; 55(11): 1561–1567.

11. Florie J, Horsthuis K, Hommes DW et al. Magnetis resonance imaging compared with ileocolonoscopy is evaluating disease severity in Crohn´s disease. Clin Gastroenterol Hepatol 2005; 3(12): 1221–1228.

12. Stathaki MI, Koukouraki SI, Karkavitsas NS et al. Role of scintigraphy in inflammatory bowel disease. World J Gastroenterol 2009; 15(22): 2693–2700.

13. Bruining DH, Loftus EV Jr. Crohn disease clinical issues and treatment: what the radiologist need to know and what the gastroenterologist want to know. Abdom Imaging 2009; 34(3): 297–302.

14. Ksiądzyna D, Semianów-Wejchert J, Nawrot U et al. Anti-Saccharomyces cerevisiae antibodies, anti-mannan Candida antibodies and fungal colonization of the gastrointestinal tract in patients with ulcerative colitis, Crohn´s disease and irritable bowel syndrome. Čes a Slov Gastroenterol Hepatol 2009; 63: 6–13.

15. Sandborn WJ, Loftus EV Jr, Colombel JF et al. Evaluation of serologic disease markers in a population – based cohort of patients with ulcerative colitis and Crohn´s disease. Inflamm Bowel Dis 2001; 7(3): 192–201.

16. Sýkora J, Varvařovská J, Stožický F et al. Orgánově specifické protilátky u dětí s idiopatickými střevními záněty a jejich užití v klinické praxi. Čas Lék Čes 2000; 139(23): 735–737.

17. Austin GL, Shaheen NJ, Sandler RS. Positive and negative predictive values: use of inflammatory bowel disease serologic markers. Am J Gastroenterol 2006; 101(3): 413–416.

18. Hanauer SB, Strömberg U. Oral Pentasa in the treatment of active Crohn‘s disease: A meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol 2004; 2(5): 379–388.

19. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn‘s Disease. Cochrane Database Syst Rev 2005; 25(1): CD003715.

20. Prantera C, Scribano ML. Antibiotics and probiotics in inflammatory bowel disease: why, when and how. Curr Opin Gastroenterol 2009; 25(4): 329–333.

21. Sandborn WJ, Löfberg R, Feagan BG et al. Budesonide for maintenance of remission in patients with Crohn‘s disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol 2005; 100(8): 1780–1787.

22. Peeters M, Joossens S, Vermeire S et al. Diagnostic Value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 2001; 96(3): 730–734.

23. Koutroubakis IE, Petinaki E, Mouzas IA et al. Anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic autoantibodies in Greek patients with inflammatory bowel disease. Am J Gastroenterol 2001; 96(2): 449–454.

24. Vasiliauskas EA, Kam LY, Karp LC et al. Marker antibody expression stratifies Crohn´s disease into immunologically homogenous subgroups with distinct clinical characteristics. Gut 2000; 47: 487–496.

25. Forcione DG, Rosen MJ, Kisiel JB, Sands BE. Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn´s disease. Gut 2004; 53: 1117–1122.

26. Desir B, Amre DK, Lu SE et al. Utility of serum antibodies in determining clinical course in pediatric Crohn´s disease. Clin Gastroenterol Hepatol 2004; 2(2): 139–146.

27. Dubinsky MC, Lin YC, Dutridge D et al. Serum immune responses predict rapid disease progression among children with Crohn´s disease: immune responses predict disease progression. Am J Gastroenterol 2006; 101(2): 360–367.

28. Koutroubakis IE, Drygiannakis D, Karmiris K et al. Pancreatic autoantibodies in Greek patients with inflammatory bowel disease. Dig Dis Sci 2005; 50(12): 2330–2334.

29. Mottet C, Juillerat P, Pittet V et al. Pregnancy and breastfeeding in patients with Crohn‘s disease. Digestion 2007; 76(2): 149–160.